Dean's Professor of Medical Science, Professor of Medicine and Professor of Health Services, Policy & Practice:
Phone: +1 401 793 7152
Timothy P. Flanigan has spearheaded both clinical care and clinical research programs for improved HIV treatment among marginalized communities. He has been funded through the CDC, NIH, Substance Abuse and Mental Health Services Administration (SAMSA) and Ryan White to provide improved HIV treatment and prevention among individuals in jail and prison and among active substance abusers. He is also currently engaged in HIV treatment programs in Ghana and Ukraine.
Dr. Flanigan is a member of the Division of Infectious Diseases at Rhode Island and The Miriam Hospitals and Brown Medical School.
He came to Brown Medical School in 1991 to help establish a network of primary care for HIV infected individuals with a particular focus on women, substance abusers and individuals leaving prison.
Dr. Flanigan developed the HIV Core Program at the State Prison to provide care for HIV infected individuals and link them to community based resources upon release. Over 70% of individuals in Rhode Island who are HIV infected link with primary medical care at The Immunology Center.
Dr. Flanigan has been the PI on two special projects of national significance funded by HRSA to develop combined therapy for opiate addiction and HIV, as well as a model program of linkage to care for HIV positive person's leaving jail. He is also associate director of The Miriam/Brown Fogarty Program which trains and mentors overseas investigators in HIV/AIDS.
He was the recipient of a community health leadership award from The Robert Wood Johnson Foundation for the development of outstanding primary care for underserved HIV infected individuals. In 2005, he received an honorary doctorate from Salve Regina University for his support of educational opportunities for children of incarcerated parents.
Timothy P. Flanigan's initial research focused on parasitic infections including Schistosoma mansoni and Cryptosporidium parvum. As effective therapy for HIV became available, Cryptosporidiosis which is a leading cause of diarrheal illness in persons with AIDS has disappeared. Dr. Flanigan subsequently shifted his research focus to HIV care in underserved communities, particularly substance abusers, women, inner-city communities and incarcerated men and women. His early work demonstrated the feasibility of linking individuals with HIV in prison and jail to care in the community after release. The success of this program led to the implementation nationwide of programs of integrated case management that linked HIV-infected persons with medical care upon release. Importantly, among women with HIV, recidivism rates were reduced with this intervention.
Timothy P. Flanigan has since focused on the importance of routine testing for HIV in underserved communities. Approximately ¼ of the HIV infected individuals in this country are unaware of their condition and are not receiving medical care. Programs are underway to evaluate routine HIV testing (and in certain cases rapid testing) in jails, universities, TB clinics, and the primary care setting.
Timothy P. Flanigan has spearheaded a program of intense observed therapy for HIV treatment for individuals who are marginalized and would otherwise not receive the benefit of our new combination HIV treatments. A pilot program for active substance abusers to provide community based treatment strategies is ongoing and has been cited nationally. This work has been presented at the Infectious Disease Society of America, the Conference on New Advances in HIV Therapies sponsored by the American Federation for AIDS Research, and the National Retroviral Conference, and received funding through an RO1 from the National Institutes of Health. Programs to extend these community based therapies for pregnant women and persons leaving prison have begun.
1990 Burroughs Wellcome National Foundation for Infectious Diseases (NFID) Young Investigator's AwardYoung Investigator's Award
1991 Sponsorship of Irwin Lapin Student Research Award
1996 Graduation speaker, Brown University School of Medicine
1996 Brown University Faculty Teaching Award
1997, 1999 Marshall, Brown University School of Medicine Graduation Procession
2000 Robert Wood Johnson Community Health Leadership Award
2002 Francesco Cannistra, M.D., Memorial Award. Thundermist Health Center, Woonsocket, RI
2003 Profiles in Competence Award for Ability II "Using Basic Science in the Practice of Medicine." Awarded by 3rd and 4th Year Brown Medical School Students.
2004 Invited Graduation Speaker and recipient of Honorary Degree, Doctor of Humane Letters, Salve Regina University
2004 Brown Medical School Faculty Award for teaching Brown Medical Students the Art of Serving Humanity
1987-1991 AIDS Housing Council Board Member, Cleveland, Ohio.
--Board President, 1990
1988-1991-Residency Education Committee, University Hospitals of Cleveland
1989-1991 Enteric Pathogen Study Group: AIDS Clinical Trials Groups (ACTG); National Institutes of Health (NIH)
1991-Present Board Member, Sunrise Community Housing, now AIDS Care Ocean State, RI
1992-1995 Member, Brown University AIDS Program
1993-Present Executive Committee, Fogarty Program, International Health Institute, Brown University
1995-Present Associate Director, Brown University AIDS Program
1996 Chair, Collaborative Mucosal Immunity Group; National Collaborative Vaccine Development Group, NIH. Invited meeting (February, 1996). Washington, D.C.
1998 Committee on Perinatal Transmission of HIV. Workshop. National Academy of Sciences, Institute of Medicine. Washington, DC. Invited presenter (April 1, 1998).
1999-Present Executive Committee, International Health Institute, Brown University
2002 Reviewer. NIH/National Institute of Allergy and Infectious Diseases (NIAID) Topical Microbicides Program Project Reverse Site Visit (January 9-10, 2002). Washington, DC.
2002 Team Leader, Section on Cryptosporidiosis and Microsporidiosis, Section on Bacterial Infections for Opportunistic Infections Treatment Guidelines (April 15, 16, 2002). Panel convened by the Centers for Disease Control and Prevention (CDC) and NIH.
2002-present Data Safety Management Board (DSMB) for NIH/ The National Institute of Mental Health (NIMH)
2004-2008 Clinical Research Review Committee, National Center for Research Resources. NIH.
2004 Abstract Reviewer, International AIDS conference. Bangkok, Thailand (July 11-16, 2004).
2004-present Member, Board of Directors, Doctors of the World
2004-2008 Member, Clinical Research Review Committee (CRRC), NIH/ National Center for Research Resources (NCRR). Bethesda, MD
2005-2007 Advisory Committee on Voluntary Foreign Aid (ACVFA), US Agency for International Development (USAID)
Dr. Flanigan precepts medical students, residents and fellows in HIV care at The Miriam Hospital Immunology Center as well as at the Rhode Island Adult Correctional Institute. He lectures on HIV/AIDS therapies both in the United States and internationally.
Title: University of Ghana-Brown University Academic Partnership to Address HIV/AIDS
Funding Agency: Higher Education for Development
Funding Period: Two Years
Two Year Total: $1,100,000
Funding Status: Project funded -
Center for Metabolic Research on HIV and Drug Use
Principal Investigator: Sherwood Gorbach, MD
Agency: NIH/NIDA P30DA013868
$40, 043, .9 Calendar Months
The goal of the Center is to continue to work to raise awareness of the importance of nutritional and metabolic disorders on outcomes in the drug using population and to encourage investigators to include studies of nutritional and metabolic status n their research in drug using populations.
HIV and Other Infectious Consequences of Substance Abuse
Principal Investigator: Timothy P. Flanigan, MD
Agency: NIH/NIDA 2T32DA13911
$386,345/year, .6 Calendar Months
The goal of this training program is to prepare postdoctoral fellows (physicians and behavioral scientists) for research careers in the cross-disciplinary field of HIV and other infections associated with substance abuse
Optimizing HIV Care in Less Developed Countries
Principal Investigator: Kenneth Freedberg, MD
Agency: NIH/NIAID, 2R01A1058736
$31,269, .6 Calendar Months
This new model will reflect the most current understanding of HIV and AIDS epidemiology, treatment efficacy, impact on TB transmission and cost-effectiveness of care.